CD8A and neoplasm: Despite continuous advances, the choice of the best antigen formulation for human cancer vaccines remains a challenge, and suitable preclinical models are required to investigate the immunogenicity of new human tumor antigens and functionally characterize the CD4+ and CD8+ T cell responses elicited in vivo.